dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Álamo, Mª del Carmen |
dc.contributor.author | Ochenduszko, Sebastian |
dc.contributor.author | Crespo, Guillermo |
dc.contributor.author | Corral, Mónica |
dc.contributor.author | Oramas, Juana |
dc.contributor.author | Sancho, Pilar |
dc.contributor.author | Muñoz Couselo, Eva |
dc.date.accessioned | 2022-05-13T12:39:16Z |
dc.date.available | 2022-05-13T12:39:16Z |
dc.date.issued | 2021-11-27 |
dc.identifier.citation | Álamo MC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, et al. Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-MutatedMetastatic Melanoma in Routine Clinical Practice. Onco Targets Ther. 2021 Nov 27;14:5345-5352. |
dc.identifier.issn | 1178-6930 |
dc.identifier.uri | https://hdl.handle.net/11351/7530 |
dc.description | BRAF; Cobimetinib; Vemurafenib |
dc.description.abstract | Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.
Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAFV600 mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR < 12 months). Secondary endpoints included treatment adherence, labor productivity, anxiety/depression, and safety profile.
Results: During the combination therapy, 12 patients (29.3%) had a CR, 19 a PR (46.3%), 5 showed SD (12.2%), and 5 had PD. A total of 12 patients (29.3%) were considered as achieving a durable response and 29 (70.7%) as a non-durable one. Practically all sociodemographic and clinical characteristics were similar between patients. Body mass index was the only differential factor (with higher body mass index achieving a non-durable response). The treatment adherence was 100% in patients with durable response and 66.7% in those with non-durable.
Conclusion: The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients. |
dc.language.iso | eng |
dc.publisher | Dove Medical Press |
dc.relation.ispartofseries | OncoTargets and Therapy;14 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Melanoma - Tractament |
dc.subject | Metàstasi |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Melanoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoplasm Metastasis |
dc.subject.mesh | Treatment Outcome |
dc.title | Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2147/OTT.S325208 |
dc.subject.decs | melanoma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | metástasis neoplásica |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.2147/OTT.S325208 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Álamo MC] Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Ochenduszko S] Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain. [Crespo G] Oncology Department, Hospital Universitario de Burgos, Burgos, Spain. [Corral M] Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Oramas J] Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Sancho P] Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Muñoz-Couselo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34866914 |
dc.identifier.wos | 000723709200002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |